Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tysabri's rebounders

Biogen Idec Inc. is not much concerned about evidence published last week that stopping treatment of multiple sclerosis patients with Tysabri natalizumab may lead to a "rebound" of increased disease activity.

Researchers from the MS Center at

Read the full 363 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers